L & S Advisors’s Novavax NVAX Stock Holding History

L & S Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,500	Closed	-$311K	–	330
2021 Q3	$311K	Buy	+1,500	New	+$331K	0.03%	282

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

L & S Advisors's NVAX Position: Q4 2021 in Review

L & S Advisors sold out of Novavax (NVAX) in Q4 2021, closing a stake of 1,500 shares — an estimated $311K sold.

L & S Advisors first reported a position in NVAX in Q3 2021 and held it in 1 quarter. The position peaked at $311K in Q3 2021. 429 funds tracked by Wall St. Rank hold NVAX as of Q4 2021.

L & S Advisors reported no remaining Novavax position as of Q4 2021 after selling out during the quarter.
L & S Advisors sold 1,500 Novavax shares in Q4 2021, an estimated $311K.
L & S Advisors first reported a position in Novavax in Q3 2021 and held it in 1 quarter.
L & S Advisors's Novavax position peaked at $311K in Q3 2021.
429 funds tracked by Wall St. Rank held Novavax as of Q4 2021.

Based on L & S Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.